EDIT editasmedicine.com: Future Profit

Editas Medicine Inc (EDIT) - corporate logo

Editas Medicine, Inc. (EDIT) conducts its development within a stable US environment, shielded from external political risks. However, the company faces intense patent battles in the CRISPR field. The consensus earnings forecast visualizes these trends, where determines the latest valuation metric. The business model relies on full production outsourcing, focusing resources exclusively on research and intellectual property.

EDIT: Editas Medicine, Inc. Projected Future Earnings 07/04/2022 - 11/18/2026

Editas Corp - analytical breakdowns and key metrics (EDIT)

- share price and consensus valuation forecast:
Comprehensive company analysis:Editas Corp, EDIT
Brand item of Editas

This indicator reflects the business's expected net income relative to its current market capitalization, allowing for the determination of the asset's degree of overvaluation. By analyzing the forward net income metric, an investor sees the result of daily guidance recalculations, which is critically important for Editas Medicine, Inc. (EDIT), as a stable R&D environment in the US minimizes geopolitical risks when assessing future revenues from gene editing.

Competitors of Editas Medicine, Inc.

Expected Profit Tempus AI|Projected Future Earnings Qiagen|Projected Future Earnings IONS|Expected Profit RGEN (Repligen Corp.)|Avidity - Future Profit|CRSP (crisprtx.com) - Forward Earnings|WGS: Future Profit|Projected Net Profit Ultragenyx (RARE)|BEAM: Projected Future Earnings|Sarepta Therapeutics, Inc. (SRPT) - Projected Future Earnings|TWST (twistbioscience.com) - Projected Future Earnings|10x Genomics, Inc. (TXG) - Company Profit Forecast|Future Profit NTLA (Intellia Therapeutics, Inc.)|STOK - Expected Net Profit|Expected Profit biolifesolutions.com BLFS|Company Profit Forecast Wave Life Sciences Corp (WVE)|MAZE - Expected Profit|Expected Net Income SION (Sionna Therapeutics Inc)|PRME: Projected Future Earnings|Taysha - Expected Net Income|Expected Profit uniQure NV|Net Profit Forecast MGTX (MeiraGTx PLC)|Future Profit RGNX (regenxbio.com)|Solid Biosciences Inc. - Net Profit Forecast|Expected Profit Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Expected Net Profit|BNTC - Expected Profit|Design Pharma - Future Net Profit|RCKT (Rocket Pharmaceuticals Inc) - Future Profit|4D Molecular Therapeutics (FDMT) - Projected Future Earnings|Expected Profit Lexeo Therapeutics, Inc.|Expected Net Profit Korro Bio, Inc. KRRO|Expected Profit Silence Therapeutics Corp (SLN)|PRQR (ProQR) - Expected Net Income|Projected Future Earnings CDXS (Codexis, Inc.)|Company Profit Forecast sangamo.com (SGMO)|nautilus.bio - Projected Future Earnings|Metagenomi (MGX) - Future Profit|DTIL: Projected Future Earnings|Expected Net Profit Generation Bio Co (GBIO)|BOLD (Boundless Bio) - Projected Future Earnings|Future Profit Exicure (XCUR)|Expected Profit Celsion Corporation (IMNN)|PHIO - Expected Net Profit|Mustang Bio Inc - Future Profit|Projected Future Earnings transcodetherapeutics.com RNAZ|Bionano Genomics Inc. - Projected Future Earnings|APDN (Applied DNA Sciences) - Net Profit Forecast|BLUE (bluebirdbio.com) - Future Profit|Net Profit Forecast IPA|OMGA (omegatherapeutics.com) - Projected Future Earnings|Singular Genomics Systems Inc (OMIC) - Company Profit Forecast|Projected Future Earnings RGLS|Company Profit Forecast Syros Pharmaceuticals, Inc.|Expected Profit Telesis Bio Inc. TBIO|Future Net Profit TCON (TRACON Pharmaceuticals Inc.)|Unity Bio - Projected Future Earnings